As multiple new drugs like antibody-drug conjugates (ADCs) become available for SCLC, the critical research question will shift from *if* they work to *when* they should be used. Future biomarker strategies must focus on optimizing treatment sequences, considering factors like the drug's target and payload.

The rationale for combining ADCs with checkpoint inhibitors extends beyond additive effects. Preclinical data shows ADCs can increase T-cell infiltration into the tumor, potentially turning immunologically 'cold' tumors 'hot.' This offers a promising synergistic strategy, especially for PD-L1 negative patients who typically don't respond to immunotherapy alone.

Oncologists hypothesize that using the T-cell engager Tarlatumab after chemotherapy has reduced tumor volume may be a safer strategy. Real-world evidence suggests high tumor burden increases the risk of severe Cytokine Release Syndrome (CRS), so using chemotherapy to first cytoreduce the cancer could mitigate this toxicity.

Dr. Patrick Baeuerle suggests that instead of engineering complex co-stimulatory signals into T-cell engagers, a more effective strategy is to combine them with standard-of-care treatments like chemotherapy or ADCs. This approach dramatically augments efficacy and has already prompted multiple Phase 3 trials.

Small cell lung cancer tumors are immunologically "cold" with few T-cells, limiting standard immunotherapy efficacy. Tarlatumab, a BiTE, physically links T-cells to tumor cells via the DLL-3 target, forcing an immune synapse and helping the immune system attack a tumor it would otherwise ignore.

While immunotherapy was a massive leap forward, Dr. Saav Solanki states the next innovation frontier is combining it with newer modalities. Antibody-drug conjugates (ADCs) and T-cell engagers are being used to recruit the immune system into the tumor microenvironment, helping patients who don't respond to current immunotherapies.

In notoriously hard-to-treat small cell lung cancer (SCLC), ADCs are emerging as a crucial next step. They hold promise for patients who progress after chemoimmunotherapy and newer targeted agents like tarlatamab, a setting where treatment options are currently scarce. ADCs could provide meaningful responses in this significant unmet need.

Despite being "targeted therapies," multiple promising antibody-drug conjugates (ADCs) for small cell lung cancer (SCLC) show no correlation between the target protein's expression level and patient response. This suggests the payload or other factors are the primary drivers of efficacy, complicating biomarker development for patient selection.

Testing antibody-drug conjugate (ADC) and immunotherapy combinations in the neoadjuvant setting is strategically superior because an intact tumor's antigen load enhances T-cell priming and immunotherapy efficacy, an advantage lost in the post-surgery adjuvant setting.